These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 10452672)

  • 1. Prospective follow-up of 67 indinavir-experienced human immunodeficiency virus-infected and AIDS patients treated with the ritonavir/saquinavir combination.
    Lallemand F; Adda N; Schneider V; Jacomet C; Salhi Y; Rozenbaum W
    Clin Infect Dis; 1999 May; 28(5):1184-5. PubMed ID: 10452672
    [No Abstract]   [Full Text] [Related]  

  • 2. [Polymorphism of protease genes in patients infected with HIV-1 and response to therapy including a protease inhibitor].
    Mouroux M; Bossi P; Yvon-Groussin A; Delaugerre C; Valantin MA; Tubiana R; Coutellier A; Bonmarchand M; Bricaire F; Katlama C; Agut H; Huraux JM; Calvez V
    Pathol Biol (Paris); 1999 May; 47(5):549-52. PubMed ID: 10418038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.
    Michelet C; Ruffault A; Sébille V; Arvieux C; Jaccard P; Raffi F; Bazin C; Chapplain JM; Chauvin JP; Dohin E; Cartier F; Bellissant E
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3393-402. PubMed ID: 11709314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug interactions and protease inhibitor therapy in the treatment of HIV/AIDS.
    Klaus BD; Grodesky MJ
    Nurse Pract; 1998 Feb; 23(2):102-4, 106. PubMed ID: 9513221
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical application of HIV protease inhibitors].
    Chiba N; Shintani M; Ueno T; Hayashi H
    Tanpakushitsu Kakusan Koso; 1998 May; 43(6):744-51. PubMed ID: 9612068
    [No Abstract]   [Full Text] [Related]  

  • 6. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
    Côté HC; Brumme ZL; Harrigan PR
    J Virol; 2001 Jan; 75(2):589-94. PubMed ID: 11134271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long-term immunologic response in HIV-infected patients with CD4 cell counts Le Moing V; Eid Z; Ecobichon JL; Duval X; Longuet P; Elbim C; Brun-Vezinet F; Leport C; Vilde JL
    Ann Med Interne (Paris); 2001 Feb; 152(1):11-4. PubMed ID: 11240420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abacavir (1592) with protease inhibitors in potent antiretroviral activity.
    AIDS Patient Care STDS; 1998 Apr; 12(4):315-6. PubMed ID: 11361959
    [No Abstract]   [Full Text] [Related]  

  • 9. [HIV protease inhibitors. A new drug class in antiretroviral therapy].
    Mauss S; Seidlitz B; Jablonowski H; Häussinger D
    Dtsch Med Wochenschr; 1996 Nov; 121(44):1369-74. PubMed ID: 8964223
    [No Abstract]   [Full Text] [Related]  

  • 10. [Antiretroviral treatment in human immunodeficiency virus infection].
    Blum L; Bachmeyer C
    Ann Dermatol Venereol; 1997; 124(9):641-54. PubMed ID: 9739932
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
    Casado JL; Dronda F; Hertogs K; Sabido R; Antela A; Martí-Belda P; Dehertogh P; Moreno S;
    AIDS Res Hum Retroviruses; 2001 Jan; 17(2):93-8. PubMed ID: 11177388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The choice of HIV protease inhibitor: indinavir is currently the best option.
    Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AmFAR extols FDA on rapid approval of two protease inhibitors.
    AIDS Patient Care STDS; 1996 Jun; 10(3):193-4. PubMed ID: 11361645
    [No Abstract]   [Full Text] [Related]  

  • 14. Viramune cleared for use in combination with protease inhibitors.
    AIDS Patient Care STDS; 1998 Nov; 12(11):872. PubMed ID: 11362046
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients.
    Marcelin AG; Flandre P; de Mendoza C; Roquebert B; Peytavin G; Valer L; Wirden M; Abbas S; Katlama C; Soriano V; Calvez V
    Antivir Ther; 2007; 12(2):247-52. PubMed ID: 17503666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of HIV protease inhibitors: a survey.
    Ren S; Lien EJ
    Prog Drug Res; 1998; 51():1-31. PubMed ID: 9949858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [HIV protease inhibitors].
    Rubio R; Romeu J; Viciana P; Redondo C
    Enferm Infecc Microbiol Clin; 1996 Oct; 14 Suppl 1():10-4. PubMed ID: 9053020
    [No Abstract]   [Full Text] [Related]  

  • 18. A patient's guide to protease inhibitors.
    Elperin A; Sax P
    AIDS Clin Care; 1996 Oct; 8(10):83-4. PubMed ID: 11363988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Data in from first head-to-head protease inhibitor.
    AIDS Patient Care STDS; 1998 Apr; 12(4):317. PubMed ID: 11361961
    [No Abstract]   [Full Text] [Related]  

  • 20. Antiretroviral therapy: a guide to the most important trials.
    Rutschmann O; Hirschel B
    Schweiz Med Wochenschr; 1997 Mar; 127(11):436-43. PubMed ID: 9098917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.